1. Market Research
  2. > Pharmaceutical
  3. > Generic Drug Market Trends
  4. > Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines

This research was designed to provide pharmaceutical sales, marketing, and brand management with data to better understand how US patients will make decisions regarding their purchase and use of biosimilar medications.

Table Of Contents

Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines
Copyright and usage guidelines 4
Introduction 5
Methodology 6
Data collection and screening criteria 6
Sample source and geography 6
Statistical significance 6
Executive summary 8
Relative medication attribute importance 10
Summary of key perceptions 12
Respondent demographics 16
Current use of prescription drugs 17
Respondent age 19
Education level 21
Household income 23
Health insurance coverage 25
Number of drugs taken, past 6 months 29
Main medication type 30
Medication decision-making 32
Medication brand decision-maker 33
Frequency of requesting a generic 35
Willingness to switch to a generic against doctor's orders: Simple medication 37
Willingness to switch to a generic against doctor's orders: Complex medication.39
Physician discussions: Safety vs. Efficacy 41
Segment differences 41
Frequency of consulting a pharmacist on drug decisions 43
Prescription choice models 45
Output/ Findings 48
Medication perceptions 50
Perception: Medication effectiveness is the same for everyone 51
Perception: Medication safety is the same for everyone 53
Attributes of a “complex medication” 55
Perception: Generics are an exact copy of the original 57
Perception: Types of companies that make generic medications 59
Biologic drug perceptions 61
Familiarity with biologic medicine 62
Reaction to the phrase “biologic medication” 64
Pharmaceutical industry perceptions 66
Importance of the medication production company 67
Trust in the quality of medications from geographic regions 69
Segment differences - Brazil 70
Segment differences - Canada 71
Segment differences - China 72
Segment differences - France 73
Segment differences - Germany 74
Segment differences - India 75
Segment differences - Israel 76
Segment differences - Japan 77
Segment differences - Mexico 78
Segment differences - Russia 79
Segment differences - South Korea 80
Segment differences - United Kingdom 81
Segment differences - United States 82
Pharmaceutical manufacturer brand recognition 83
Segment differences - Amgen 84
Segment differences - AstraZeneca 85
Segment differences - Biogen Idec 86
Segment differences - Dr. Reddy 87
Segment differences - Eli Lilly 88
Segment differences - Johnson and Johnson 89
Segment differences - Merck 90
Segment differences - Pfizer 91
Segment differences - Ranbaxy 92
Segment differences - Roche 93
Segment differences - Sandoz 94
Segment differences - Teva 95
Segment differences - Watson 96
About Industry Standard Research 97

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Biosimilar - Global Market Outlook (2016-2022)

Biosimilar - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • September 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Biosimilars market is estimated to be $3.5 billion in 2015 with a CAGR of 23.8% is poised to reach $15.6 billion by 2022. High end adoption of off patented drugs ...

Insulin Biosimilars - Global Market Outlook (2016-2022)

Insulin Biosimilars - Global Market Outlook (2016-2022)

  • $ 4157
  • Industry report
  • October 2016
  • by Stratistics MRC

According to Stratistics MRC, the Global Insulin Biosimilars market is accounted for $xx million in 2015 and is expected to reach $xx million by 2022 growing at a CAGR of xx% from 2015 to 2022. Growing ...

The Future of Generic Drugs and Strategies for Commercial Success

The Future of Generic Drugs and Strategies for Commercial Success

  • $ 2995
  • Industry report
  • September 2016
  • by CBR Pharma Insights

The Future of Generic Drugs and Strategies for Commercial Success Summary GBI Research’s latest report “The Future of Generic Drugs and Strategies for Commercial Success” discusses trends in the ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.